Bristol-Myers Squibb Co. and Pfizer Inc. on Monday filed a slew of patent infringement suits in Delaware to protect their patents for the successful drug Eliquis and halt the development of generic versions of the profitable blood thinner.
The companies, which jointly develop the drug, targeted at least 13 generic drugmakers in cases filed in the U.S. District Court for the District of Delaware, bringing the total tally to no less than 16. The flurry of litigation kicked off last week with a case filed against Mylan Inc. The new cases were filed Monday and entered to an online docket tracking system Tuesday morning.
